A permeation-enhanced non-scrotal testosterone transdermal system for the treatment of male hypogonadism

This publication has 56 references indexed in Scilit:

• Testosterone Supplementation for Hypogonadal Impotence: Assessment of Biochemical Measures and Therapeutic Outcomes
  Journal of Urology, 1997
• Pharmacokinetics of Testosterone in Hypogonadal Men After Transdermal Delivery: Influence of Dose
  The Journal of Clinical Pharmacology, 1996
• Prostate volume in testosterone‐treated and untreated hypogonadal men in comparison to age‐matched normal controls
  Clinical Endocrinology, 1994
• Transdermal Dihydrotestosterone Treatment of 'Andropause'
  Annals of Medicine, 1993
• Enhanced transdermal delivery of testosterone across nonscrotal skin produces physiological concentrations of testosterone and its metabolites in hypogonadal men
  Journal of Clinical Endocrinology & Metabolism, 1992
• Osteopenia in Men with a History of Delayed Puberty
  New England Journal of Medicine, 1992
• A biodegradable testosterone microcapsule formulation provides uniform eugonadal levels of testosterone for 10-11 weeks in hypogonadal men
  Journal of Clinical Endocrinology & Metabolism, 1992
• Chromosome abnormalities found among 34910 newborn children: results from a 13-year incidence study in rhus, Denmark
  Human Genetics, 1991
• Adverse dermatologic reactions to transdermal drug delivery systems
  Journal of the American Academy of Dermatology, 1990
• Regional Variation in Percutaneous Penetration of 14C Cortisol in Man**From the Division of Dermatology, Department of Medicine, University of California School of Medicine, San Francisco, California 94122.
  Journal of Investigative Dermatology, 1967